Liproxstatin-1 analog is primarily utilized in research focused on addressing oxidative stress-related conditions. It serves as a potent inhibitor of ferroptosis, a form of regulated cell death driven by lipid peroxidation. This makes it valuable in studying neurodegenerative diseases, such as Alzheimer's and Parkinson's, where ferroptosis is implicated. Additionally, it is explored in cancer research to understand its potential in protecting healthy cells during chemotherapy, which often induces oxidative damage. The analog is also investigated in ischemia-reperfusion injury models, particularly in cardiac and renal tissues, to mitigate damage caused by the restoration of blood flow after ischemia. Its application extends to preclinical studies aiming to develop therapeutic strategies for diseases linked to oxidative stress and lipid metabolism.